- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02480842
Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction
Randomized Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction
Study Overview
Status
Conditions
Detailed Description
Methods:
Patients will be recruited just after surgery scheduling. They will undergo preoperative evaluation one week before the surgery on average. At this moment, preoperative analysis will be conducted with personal data and medical history. Patients will undergo new assessments 07, 15, 30, 60, 90 and 180 days after surgery, periods that will be described as PO 07, PO 15, PO 30, PO 60, PO 90 and PO 180.
All patients will receive standard physiotherapy treatment for women undergoing breast reconstruction from Physical Therapy Sector of Mastology Discipline of the Department of Gynecology of Federal University of São Paulo. The protocol consists of early exercise, limited to 90° of shoulder range of motion (ROM), starting the day after the surgery and repeated 7 days after surgery.
After 15 days of surgery, the patients will be randomized into two treatment protocols.
However, because of the existence of different types of reconstructive surgery, randomization will performed from two groups:
- Alloplastic group: patients who will undergo reconstruction with tissue expander or breast implant
- Oncoplastic Group: patients who will undergo mammaplasty and / or contralateral symmetrization
Computer random sequence will be used for randomization, in which each group will be randomized to Group A or Group B.
- Subgroup A: Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain.
- Subgroup B: Patient will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction
At the end of randomization there will be four subgroups: alloplastic A, alloplastic B, oncoplastic A and oncoplastic B
Outcomes:
Shoulder range of motion:
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation. The movements will be performed actively. The patient will be positioned in the sitting position. To assess shoulder flexion, the upper limb will be in neutral position with elbow extension. Patient will be asked to raise the arm forward, close to the body. To assess extension, the arm will be positioned with 90° of elbow flexion and the patient will be asked to take the arm back. For adduction, the patient will be with 90° of shoulder flexion with the palm down and patient will be told to move the arm medially. For the study of the upper limb abduction, the limb will be in supination and elbow extension and the patient will be asked to raise the arm to the side, along the trunk line toward the ear. For the evaluation of internal rotation and external rotation the upper limb will be placed in 90° of shoulder abduction and 90° of elbow flexion. The patient will be asked to rotate the shoulder internally and externally, respectively.
Pain:
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain. The patient will be asked if there is pain at the moment of evaluation , and to describe the place and the degree of the pain.
Upper limbs function:
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used. It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms. It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities. The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application. The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
Dehiscence:
Dehiscence wil be assessed by inspection and palpation. It will be described "presence" or "absence" of dehiscence and its location. The wound conditions will be described, with observation of necrosis and infection. Signs of infection such as redness, hyperthermia and secretion will be reported. The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape). Photographic record of dehiscence will be done, for better analysis and comparison of evolution. A Nikon Coolpix S3000 camera will be used.
- Seroma:
The seroma evaluation will be performed by inspection and palpation. There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
São Paulo, Brazil, 04024002
- Federal University of São Paulo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with breast cancer, who will be submitted to breast surgery (radical or conservative), followed by immediate reconstruction: alloplastic (tissue expander or breast implant) or oncoplastic (breast reduction or contralateral symmetrization).
Exclusion Criteria:
- Patients that will be submitted to bilateral oncology surgery, reconstruction with autologous tissue or breast surgery without reconstruction. Patients with motor or neurological deficits prior to surgery, with cognitive impairment and those that do not accept to participate.
- Patients who need to undergo new surgical procedures during the postoperative follow-up period and those who do not appear to postoperative evaluations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Alloplastic group A
After randomization (15 days after surgery): - Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain. |
|
|
Experimental: Alloplastic group B
After randomization (15 days after surgery): - Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction |
|
|
Experimental: Oncoplastic group A
After randomization (15 days after surgery): - Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain. |
|
|
Experimental: Oncoplastic group B
After randomization (15 days after surgery): - Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 07 days after surgery assessment
Time Frame: One week before surgery on average and 07 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 07 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 15 days after surgery assessment
Time Frame: One week before surgery on average and 15 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 15 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Time Frame: One week before surgery on average and 30 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 30 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 60 days after surgery assessment
Time Frame: One week before surgery on average and 60 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 60 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Time Frame: One week before surgery on average and 90 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 90 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 180 days after surgery assessment
Time Frame: One week before surgery on average and 180 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 180 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 07 days after surgery assessment
Time Frame: One week before surgery on average and 07 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 07 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 15 days after surgery assessment
Time Frame: One week before surgery on average and 15 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 15 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Time Frame: One week before surgery on average and 30 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 30 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 60 days after surgery assessment
Time Frame: One week before surgery on average and 60 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 60 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Time Frame: One week before surgery on average and 90 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 90 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 180 days after surgery assessment
Time Frame: One week before surgery on average and 180 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 180 days after surgery
|
|
Change in upper limbs function from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Time Frame: One week before surgery on average and 30 days after surgery
|
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used.
It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms.
It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities.
The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application.
The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
|
One week before surgery on average and 30 days after surgery
|
|
Change in upper limbs function from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Time Frame: One week before surgery on average and 90 days after surgery
|
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used.
It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms.
It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities.
The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application.
The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
|
One week before surgery on average and 90 days after surgery
|
|
Dehiscence at 07 days after surgery assessment
Time Frame: 07 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
07 days after surgery
|
|
Dehiscence at 15 days after surgery assessment
Time Frame: 15 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
15 days after surgery
|
|
Dehiscence at 30 days after surgery assessment
Time Frame: 30 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
30 days after surgery
|
|
Dehiscence at 60 days after surgery assessment
Time Frame: 60 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
60 days after surgery
|
|
Dehiscence at 90 days after surgery assessment
Time Frame: 90 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
90 days after surgery
|
|
Seroma at 07 days after surgery assessment
Time Frame: 07 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
07 days after surgery
|
|
Seroma at 15 days after surgery assessment
Time Frame: 15 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
15 days after surgery
|
|
Seroma at 30 days after surgery assessment
Time Frame: 30 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
30 days after surgery
|
|
Seroma at 60 days after surgery assessment
Time Frame: 60 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
60 days after surgery
|
|
Seroma at 90 days after surgery assessment
Time Frame: 90 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
90 days after surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FUSaoPaulo PT 3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Emory UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary CarcinomaUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingBreast Cancer | Triple -Negative Breast CancerChina
-
Harbin Medical UniversityActive, not recruitingBreast Cancer Triple Negative Breast CancerChina
Clinical Trials on Alloplastic free ROM
-
Suez Canal UniversityNot yet recruitingAlveolar Ridge Preservation | Dental Implant Placement
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Completed
-
The Catholic University of AmericaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Suez Canal UniversityNot yet recruitingSocket Preservation | Tooth Extraction
-
Duzce UniversityCompleted
-
Centers for Disease Control and PreventionUniversity of Colorado, DenverCompleted
-
Necmettin Erbakan UniversityNot yet recruiting
-
Golden Jubilee National HospitalUnknown
-
University of California, DavisLaborie Medical Technologies Inc.Not yet recruitingPregnancy of Unknown Location (PUL)
-
Cairo UniversityRecruiting